Dual add‐on therapy of gemigliptin and dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin alone: The SOLUTION 2 study

Documenti analoghi

• Efficacy and safety of dapagliflozin add‐on to evogliptin plus metformin therapy in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled study
  di: In‐Kyung Jeong, et al.
  Pubblicazione: (2024)
• A 52‐week efficacy and safety study of enavogliflozin versus dapagliflozin as an add‐on to metformin in patients with type 2 diabetes mellitus: ENHANCE‐M extension study
  di: Tae Seo Sohn, et al.
  Pubblicazione: (2024)
• A multicentre, double‐blind, placebo‐controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add‐on therapy in type 2 diabetic patients treated with metformin and dapagliflozin
  di: Soo Lim, et al.
  Pubblicazione: (2024)
• The Moderating Effect of Perceived Susceptibility and Decision Conflict on the Relationship Between Comorbidities and Quality of Life Among Caregivers of People with Dementia
  di: Kyung Ah Cho, et al.
  Pubblicazione: (2025)
• Risk of acute kidney injury in dapagliflozin users with type 2 diabetes: A nationwide propensity score‐matched cohort study in Korea
  di: Hee‐Jin Kim, et al.
  Pubblicazione: (2025)